top of page

3-21’s Client, Atlas Clinical Research, Acquires Suncoast Clinical Research, Inc.

Columbia, MD (December 19, 2023) – Three Twenty-One is pleased to share that its client, Atlas Clinical Research (“Atlas”), has completed its acquisition of Suncoast Clinical Research, Inc. (“Suncoast”). Three Twenty-One acted as Atlas’ exclusive buy-side advisor in this transaction.

Atlas launched in April 2023 to build a robust clinical research site network through acquisitions and organic growth. Leveraging a centralized platform, the company aims to address pivotal challenges encountered by pharmaceutical sponsors. Functioning as a Biotechnology Research entity, Atlas’ mission is to bridge the gap between “what is and what’s possible.” With a focus on therapeutic areas, Atlas operates a network of sites that aim to drive clinical trial success and advance pioneering medical treatments. Over the past 30 years, sponsors and CROs have recognized the sites within Atlas’ portfolio as distinguished hubs for researching internal medicine, central nervous system disorders, gastrointestinal ailments, and infectious diseases.

Established in 1998 and led by second generation leaders Jennifer Selk and Greg Manning, Suncoast specializes in Phase II-IV clinical research across its various sites. With a wealth of experience encompassing hundreds of research studies, Suncoast has fostered strong relationships with local communities, sponsors, and CROs, positioning itself as a premier destination for clinical research in the key therapeutic areas of CNS and Metabolic Disorders. Under the guidance of CEO, Mark Scullion, Suncoast aims to amplify its influence and outreach as part of the Atlas family by capitalizing on the network's streamlined operational excellence and unified technological infrastructure. This marks the third addition of a clinical research site to Atlas’ portfolio this year, enhancing its proficiency in existing therapeutic areas and building momentum into 2024 by expanding its geographical footprint.

"We are extremely proud of our accomplishments and growth over the past 25 years, and we are very excited to start this next chapter as part of the Atlas network. We are confident this will position us well to expand our clinical trial offerings, while continuing to focus on our core values of Patient Care, Integrity, Teamwork, Community, and Diversity” expressed Jennifer Selk, Co-Owner of Suncoast Clinical Research, Inc.

"We are thrilled to announce joining the Atlas Clinical Research network of sites," recapitulated Greg Manning, Co-Owner of Suncoast Clinical Research, Inc. "marking an exciting new chapter for our organization. This step forward is a testament to our shared values, centered around patient safety, quality data, and pioneering medical innovation. This fortifies our long-term commitment to making a difference in healthcare by combining expertise, resources, and passion – ultimately elevating our ability to impact patients' lives in a positive way."

"We're thrilled to have the Suncoast team join us at Atlas Clinical Research. It's a perfect match – our resources and expertise really enhance what Suncoast already does so well. Together, we're going to do great things to serve patients in our communities. From our first meeting, it was clear that the Suncoast culture that Jennifer and Greg have established would fit with what we are building at Atlas," said Mark Scullion, CEO of Atlas Clinical Research.

About Atlas Clinical Research

Atlas operates a therapeutically-focused network of clinical sites centered on streamlined processes and integrated technology. These sites, along with their physicians, serve as a bridge connecting patients and their families to new treatments that may improve their quality of life. Specializing in infectious disease, CNS disorders, gastroenterology, and internal medicine, Atlas aims to expand its reach across the United States to cater to a wide-ranging and diverse population of waiting patients. Partnering with biopharmaceutical sponsors, Atlas is committed to expediting the advancement of healthcare, prioritizing speed, data integrity, and patient care across the portfolio. Read more:


About Three Twenty-One Capital Partners

Three Twenty-One Capital Partners is headquartered in the Baltimore-Washington Metro area, with offices in Colorado, Florida, and New York. Three Twenty-One Capital Partners specializes in providing investment banking services to family and founder-led businesses in the lower middle market. Three Twenty-One Capital Partners’ team has completed engagements with over $15 billion in transaction value. Further information is available at 



bottom of page